<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <script src="https://cdnjs.cloudflare.com/ajax/libs/Chart.js/3.7.0/chart.min.js"></script>
    <title>MS Clinical Intelligence Dashboard</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
            font-family: system-ui, -apple-system, sans-serif;
        }

        body {
            background-color: #f5f7fa;
            min-height: 100vh;
            padding: 2rem;
        }

        .container {
            max-width: 1200px;
            margin: 0 auto;
            background-color: white;
            border-radius: 1rem;
            box-shadow: 0 4px 6px rgba(0, 0, 0, 0.1);
            padding: 2rem;
        }

        .header {
            text-align: center;
            margin-bottom: 3rem;
            padding: 2rem;
            background: linear-gradient(135deg, #2c3e50, #3498db);
            border-radius: 0.5rem;
            color: white;
        }

        .header h1 {
            font-size: 2.5rem;
            font-weight: 700;
            margin-bottom: 0.5rem;
        }

        .section-title {
            font-size: 1.5rem;
            color: #2c3e50;
            margin-bottom: 2rem;
            padding-bottom: 0.5rem;
            border-bottom: 2px solid #3498db;
        }

        .timeline {
            position: relative;
            padding: 2rem 0;
            border-bottom: 2px solid #3498db;
        }

        .timeline-line {
            position: absolute;
            top: 50%;
            left: 0;
            right: 0;
            height: 4px;
            background: #070707;
            transform: translateY(-50%);
        }

        .timeline-points {
            position: relative;
            display: flex;
            justify-content: space-between;
            margin: 0 2rem;
        }

        .timeline-point {
            position: relative;
            display: flex;
            flex-direction: column;
            align-items: center;
            width: 200px;
        }

        .point {
            width: 20px;
            height: 20px;
            border-radius: 50%;
            margin: 1rem 0;
            z-index: 1;
        }

        .year {
            font-weight: 600;
            margin-bottom: 1rem;
            color: #2c3e50;
        }

        .description {
            text-align: center;
            font-size: 0.6rem;
            font-weight: bold ;
            color: #555;
            margin-top: 1rem;
            padding: 0.5rem;
            border-radius: 0.5rem;
            min-height: 80px;
            display: flex;
            align-items: center;
            justify-content: center;
        }

        .timeline-point:nth-child(1) .point { background-color: #3498db; }
        .timeline-point:nth-child(2) .point { background-color: #2ecc71; }
        .timeline-point:nth-child(3) .point { background-color: #e74c3c; }
        .timeline-point:nth-child(4) .point { background-color: #f1c40f; }
        .timeline-point:nth-child(5) .point { background-color: #9b59b6; }
        .timeline-point:nth-child(6) .point { background-color: #1abc9c; }

        .timeline-point:nth-child(odd) .description {
            background-color: #f8f9fa;
        }

        .timeline-point:nth-child(even) .description {
            background-color: #e9ecef;
        }
        .timeline-point {
            position: relative;
            display: flex;
            flex-direction: column;
            align-items: center;
            width: 200px;
        }

        .timeline-point::before {
            content: '';
            position: absolute;
            top: 40%;
            width: 3px;
            height: 30px;
            background-color: #3498db;
            z-index: 0;
        }

        .container_grid {
            max-width: 1200px;
            margin: 20px auto; /* Added 20px margin on top */
            padding: 20px;
            background: white;
            border-radius: 12px;
            box-shadow: 0 2px 4px rgba(0,0,0,0.1);
        }


        .moa-grid {
            display: grid;
            grid-template-columns: repeat(auto-fill, minmax(300px, 1fr));
            gap: 20px;
            margin-bottom: 30px;
        }

        .moa-button {
            background: white;
            border: 1px solid #e1e4e8;
            border-radius: 8px;
            padding: 15px;
            display: flex;
            align-items: center;
            cursor: pointer;
            transition: all 0.3s ease;
            position: relative;
            overflow: hidden;
        }

        .moa-button::after {
            content: '';
            position: absolute;
            width: 100%;
            height: 100%;
            top: 0;
            left: 0;
            background: rgba(255,255,255,0.1);
            transform: translateX(-100%);
            transition: transform 0.3s ease;
        }

        .moa-button:hover {
            transform: translateY(-2px);
            box-shadow: 0 4px 12px rgba(0,0,0,0.1);
        }

        .moa-button:hover::after {
            transform: translateX(0);
        }

        .moa-icon {
            width: 40px;
            height: 40px;
            border-radius: 8px;
            margin-right: 15px;
            flex-shrink: 0;
        }

        .immunomodulators { background-color: #4299e1; }
        .btk-inhibitors { background-color: #48bb78; }
        .s1p-modulators { background-color: #ed8936; }

        .moa-name {
            flex-grow: 1;
            font-weight: 600;
            color: #2d3748;
        }

        .dropdown-arrow {
            color: #718096;
            transition: transform 0.3s ease;
        }

        .active .dropdown-arrow {
            transform: rotate(180deg);
        }

        .moa-details {
            background: white;
            border-radius: 8px;
            padding: 20px;
            margin-top: 20px;
            display: none;
            box-shadow: 0 4px 6px rgba(0,0,0,0.1);
        }

        .metrics-grid {
            display: grid;
            grid-template-columns: repeat(3, 1fr);
            gap: 20px;
            margin-bottom: 30px;
        }

        .metric-card {
            background: #f8fafc;
            border-radius: 8px;
            padding: 20px;
            text-align: center;
        }

        .metric-value {
            font-size: 24px;
            font-weight: 700;
            color: #2d3748;
            margin: 10px 0;
        }

        .charts-section {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 20px;
            margin-bottom: 30px;
        }

        .chart-container {
            background: white;
            border-radius: 8px;
            padding: 20px;
        }

        @media (max-width: 768px) {
            .charts-section {
                grid-template-columns: 1fr;
            }
            
            .metrics-grid {
                grid-template-columns: 1fr;
            }
        }
        .container-tb {
        max-width: 1200px;
        margin: 0 auto;
        background: white;
        border-radius: 12px;
        box-shadow: 0 1px 3px rgba(0,0,0,0.1);
        padding: 20px;
    }

        table {
            width: 100%;
            border-collapse: separate;
            border-spacing: 0;
        }

        th {
            background: #f1f5f9;
            padding: 16px;
            text-align: left;
            font-weight: 600;
            color: #334155;
            border-bottom: 2px solid #e2e8f0;
        }

        td {
            padding: 16px;
            border-bottom: 1px solid #e2e8f0;
            vertical-align: top;
        }

        .drug-row {
            cursor: pointer;
            transition: all 0.2s ease;
        }

        .drug-row:hover {
            background-color: #f8fafc;
        }

        .drug-row.active {
            background-color: #f1f5f9;
            border-bottom: none;
        }

        .drug-name {
            display: flex;
            align-items: center;
            gap: 12px;
            font-weight: 500;
            color: #1e40af;
        }

        .drug-icon {
            width: 24px;
            height: 24px;
            display: flex;
            align-items: center;
            justify-content: center;
            transition: transform 0.3s ease;
            color: #64748b;
        }

        .drug-row.active .drug-icon {
            transform: rotate(180deg);
        }

        .drug-insights {
            display: none;
            background: #f8fafc;
        }

        .drug-insights td {
            padding: 0;
        }

        .drug-insights.show {
            display: table-row;
        }

        .insights-container {
            padding: 20px;
            border-top: 2px solid #e2e8f0;
        }

        .insights-section {
            background: white;
            border-radius: 8px;
            padding: 20px;
            margin-bottom: 16px;
            box-shadow: 0 1px 2px rgba(0,0,0,0.05);
        }

        .insights-section:last-child {
            margin-bottom: 0;
        }

        .insights-section h4 {
            color: #334155;
            margin: 0 0 12px 0;
            font-size: 1rem;
            display: flex;
            align-items: center;
            gap: 8px;
        }

        .insights-section h4::before {
            content: "•";
            color: #3b82f6;
        }

        .insights-section p {
            margin: 0;
            color: #475569;
        }

        .trial-button {
            background: #e2e8f0;
            border: 1px solid #cbd5e1;
            padding: 8px 16px;
            border-radius: 6px;
            margin-right: 8px;
            margin-top: -10px;
            margin-bottom: 10px;
            cursor: pointer;
            font-size: 0.875rem;
            color: #334155;
            transition: all 0.2s ease;
            font-weight: 500;
        }

        .trial-button:hover {
            background: #cbd5e1;
            border-color: #94a3b8;
        }

        .trial-button.active {
            background: #bfdbfe;
            border-color: #60a5fa;
            color: #1e40af;
        }

        .trial-insights {
            display: none;
            background: white;
        }

        .trial-insights.show {
            display: table-row;
        }

        .trial-insights .insights-section {
            background: #f8fafc;
            border: 1px solid #e2e8f0;
        }

        .phase-badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 12px;
            border-radius: 6px;
            background: #dbeafe;
            color: #1e40af;
            font-size: 0.875rem;
            font-weight: 500;
        }

        .company-cell {
            color: #64748b;
            text-shadow: #2d3748;
        }

        /* Additional styles for better visibility of active states */
        .drug-row td {
            border-bottom: 1px solid #e2e8f0;
            transition: border-color 0.2s ease;
        }

        .drug-row.active td {
            border-bottom-color: transparent;
        }

        .trial-insights td {
            padding: 0 16px 16px 16px;
        }
        .timeline-container-inner {
            max-width: 1200px;
            margin: 200px auto 20px auto;
        }

        .timeline-inner {
            position: relative;
            padding: 60px 0;
        }

        /* Main horizontal line */
        .timeline-inner::before {
            content: '';
            position: absolute;
            left: 0;
            right: 0;
            top: 20%;
            height: 4px;
            background: #3498db;
            transform: translateY(-50%);
        }

        .timeline-items-inner {
            display: flex;
            justify-content: space-between;
            position: relative;
        }

        .timeline-item-inner {
            flex: 1;
            position: relative;
            padding: 0 20px;
            text-align: center;
        }

        /* Dots on the line */
        .timeline-dot-inner {
            width: 20px;
            height: 20px;
            background: #fff;
            border: 4px solid #3498db;
            border-radius: 50%;
            position: absolute;
            left: 50%;
            transform: translateX(-50%);
            z-index: 2;
        }

        /* Content boxes */
        .timeline-content-inner {
            background: white;
            padding: 20px;
            border-radius: 8px;
            box-shadow: 0 4px 6px rgba(0, 0, 0, 0.1);
            margin: 15px 0;
            position: relative;
        }

        /* Alternating content boxes */
        .timeline-item-inner:nth-child(odd) .timeline-content-inner {
            margin-top: 50px;
        }

        .timeline-item-inner:nth-child(even) .timeline-content-inner {
            margin-top: -200px;
        }

        /* Vertical connector lines */
        .timeline-item-inner:nth-child(odd) .timeline-content-inner::before {
            content: '';
            position: absolute;
            top: -30px;
            left: 50%;
            width: 2px;
            height: 30px;
            background: #3498db;
            transform: translateX(-50%);
        }

        .timeline-item-inner:nth-child(even) .timeline-content-inner::before {
            content: '';
            position: absolute;
            bottom: -30px;
            left: 50%;
            width: 2px;
            height: 30px;
            background: #3498db;
            transform: translateX(-50%);
        }

        .timeline-year-inner {
            font-size: 1 rem;
            font-weight: bold;
            color: #2c3e50;
            margin-bottom: 10px;
        }

        .timeline-description-inner {
            color: #666;
            line-height: 1.6;
            font-size: 0.55rem;
            font-weight: bold;
        }

        @media (max-width: 768px) {
            .timeline-items-inner {
                flex-direction: column;
            }

            .timeline-item-inner {
                margin-bottom: 40px;
            }

            .timeline-item-inner:nth-child(even) .timeline-content-inner,
            .timeline-item-inner:nth-child(odd) .timeline-content-inner {
                margin-top: 20px;
            }
        }

        .latest-insights {
            max-width: 1200px;
            margin: 30px auto;
            background: white;
            border-radius: 12px;
            box-shadow: 0 2px 4px rgba(0,0,0,0.1);
            padding: 25px;
        }

        .latest-insights h2 {
            color: #2d3748;
            margin-bottom: 20px;
            font-size: 1.5rem;
            font-weight: 600;
        }

        .insight-category {
            margin-bottom: 15px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            overflow: hidden;
        }

        .insight-header {
            display: flex;
            align-items: center;
            justify-content: space-between;
            padding: 15px 20px;
            background-color: #f8fafc;
            cursor: pointer;
            transition: background-color 0.3s ease;
        }

        .insight-header:hover {
            background-color: #f1f5f9;
        }

        .header-title {
            font-weight: 600;
            color: #2d3748;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .header-title .category-icon {
            width: 24px;
            height: 24px;
            display: flex;
            align-items: center;
            justify-content: center;
            border-radius: 6px;
        }

        .clinical .category-icon {
            background-color: #ebf5ff;
            color: #3182ce;
        }

        .regulatory .category-icon {
            background-color: #f0fff4;
            color: #38a169;
        }

        .safety .category-icon {
            background-color: #fff5f5;
            color: #e53e3e;
        }

        .market .category-icon {
            background-color: #faf5ff;
            color: #805ad5;
        }

        .toggle-btn {
            width: 24px;
            height: 24px;
            border-radius: 50%;
            background-color: #ffffff;
            border: 1px solid #e2e8f0;
            display: flex;
            align-items: center;
            justify-content: center;
            cursor: pointer;
            transition: all 0.3s ease;
            font-size: 18px;
            color: #64748b;
        }

        .toggle-btn:hover {
            background-color: #f8fafc;
            transform: scale(1.1);
        }

        .insight-content {
            max-height: 0;
            overflow: hidden;
            transition: max-height 0.3s ease-out;
            background-color: white;
        }

        .insight-content.active {
            max-height: 500px;
            transition: max-height 0.5s ease-in;
        }

        .insight-list {
            padding: 20px;
        }

        .insight-item {
            display: flex;
            gap: 15px;
            padding: 12px;
            border-bottom: 1px solid #f1f5f9;
        }

        .insight-item:last-child {
            border-bottom: none;
        }

        .insight-date {
            min-width: 100px;
            color: #64748b;
            font-size: 0.9rem;
        }

        .insight-description {
            color: #4a5568;
            line-height: 1.5;
            flex-grow: 1;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 2px 8px;
            border-radius: 12px;
            font-size: 0.75rem;
            font-weight: 500;
            margin-left: 8px;
        }

        .badge.new {
            background-color: #ebf5ff;
            color: #3182ce;
        }

        .badge.update {
            background-color: #f0fff4;
            color: #38a169;
        }

    </style>
</head>
<body>
    <div class="container">
        <header class="header">
            <h1>Clinical Intelligence - Multiple Sclerosis</h1>
        </header>

        <section>
            <h2 class="section-title">MS Treatment Development Timeline</h2>
            <div class="timeline">
                <div class="timeline-line"></div>
                <div class="timeline-points">
                    <div class="timeline-point">
                        <div class="year">2019</div>
                        <div class="point"></div>
                        <div class="description">Discovery of BTK inhibitors with dual action targeting both B-cells and central inflammation, transforming MS treatment.</div>
                    </div>
                    <div class="timeline-point">
                        <div class="year">2020</div>
                        <div class="point"></div>
                        <div class="description">Safer subcutaneous anti-CD20 therapy introduced, improving B-cell targeting with fewer side effects.</div>
                    </div>
                    <div class="timeline-point">
                        <div class="year">2021</div>
                        <div class="point"></div>
                        <div class="description">New S1P receptor modulators offered better lymphocyte control and reduced heart risks.</div>
                    </div>
                    <div class="timeline-point">
                        <div class="year">2022</div>
                        <div class="point"></div>
                        <div class="description">First success in promoting remyelination, marking a shift towards regenerative MS treatments.</div>
                    </div>
                    <div class="timeline-point">
                        <div class="year">2023</div>
                        <div class="point"></div>
                        <div class="description">Selective microglial modulation allowed targeted CNS treatment without affecting the immune system.</div>
                    </div>
                    <div class="timeline-point">
                        <div class="year">2024</div>
                        <div class="point"></div>
                        <div class="description">Combined therapies that address both immune modulation and remyelination showed increased effectiveness.</div>
                    </div>
                </div>
            </div>
        </section>
    </div>

    <div class="container_grid">
        <h2 class="section-title">Mechanism Of Actions</h2>
        <div class="moa-grid">
            <div class="moa-button" onclick="toggleMOA('anticd20', this)">
                <div class="moa-icon immunomodulators"></div>
                <span class="moa-name">Anti CD20 monoclonal antibody</span>
                <span class="dropdown-arrow">▼</span>
            </div>
            <div class="moa-button" onclick="toggleMOA('btk', this)">
                <div class="moa-icon btk-inhibitors"></div>
                <span class="moa-name">BTK Inhibitors</span>
                <span class="dropdown-arrow">▼</span>
            </div>
            <div class="moa-button" onclick="toggleMOA('s1p', this)">
                <div class="moa-icon s1p-modulators"></div>
                <span class="moa-name">S1P Modulators</span>
                <span class="dropdown-arrow">▼</span>
            </div>
            <div class="moa-button" onclick="toggleMOA('s1p', this)">
                <div class="moa-icon immunomodulators"></div>
                <span class="moa-name">DHODH Inhibitors</span>
                <span class="dropdown-arrow">▼</span>
            </div>
            <div class="moa-button" onclick="toggleMOA('s1p', this)">
                <div class="moa-icon btk-inhibitors"></div>
                <span class="moa-name">Immunomodulators</span>
                <span class="dropdown-arrow">▼</span>
            </div>
            <div class="moa-button" onclick="toggleMOA('s1p', this)">
                <div class="moa-icon s1p-modulators"></div>
                <span class="moa-name">Anti CD40L monoclonal antibody </span>
                <span class="dropdown-arrow">▼</span>
            </div>
        </div>

        <!-- BTK Inhibitors -->
        <div id="btk-details" class="moa-details">
            <h3 class="section-title">BTK Inhibitors</h3>
            <div class="metrics-grid">
                <div class="metric-card">
                    <h3>Total Trials</h3>
                    <div class="metric-value">11</div>
                </div>
                <div class="metric-card">
                    <h3>Total Competitors</h3>
                    <div class="metric-value">5</div>
                </div>
                <div class="metric-card">
                    <h3>Drug Count</h3>
                    <div class="metric-value">6</div>
                </div>
            </div>

            <div class="charts-section">
                <div class="chart-container">
                    <canvas id="btk-phase-chart"></canvas>
                </div>
                <div class="chart-container">
                    <canvas id="btk-market-chart"></canvas>
                </div>
            </div>
            <h2 class="section-title">BTK Inhibitors Time Line</h2>
            <div class="timeline-container-inner">
                <div class="timeline-inner">
                    <div class="timeline-items-inner">
                        <div class="timeline-item-inner">
                            <div class="timeline-dot-inner"></div>
                            <div class="timeline-content-inner">
                                <div class="timeline-year-inner">2019</div>
                                <div class="timeline-description-inner">
                                    Breakthrough discovery: First demonstration of BTK inhibitor evobrutinib's efficacy in reducing MS lesions in Phase II trials, establishing BTK as a viable therapeutic target in MS.
                                </div>
                            </div>
                        </div>
        
                        <div class="timeline-item-inner">
                            <div class="timeline-dot-inner"></div>
                            <div class="timeline-content-inner">
                                <div class="timeline-year-inner">2020</div>
                                <div class="timeline-description-inner">
                                    Olebrutinib emerges as a leading CNS-penetrant BTK inhibitor with positive Phase II results showing significant reduction in brain lesions and clinical outcomes.
                                </div>
                            </div>
                        </div>
        
                        <div class="timeline-item-inner">
                            <div class="timeline-dot-inner"></div>
                            <div class="timeline-content-inner">
                                <div class="timeline-year-inner">2021</div>
                                <div class="timeline-description-inner">
                                    Fenebrutinib launches pivotal Phase III FENhance clinical trial program, marking the expansion of BTK inhibitor options in MS treatment landscape.
                                </div>
                            </div>
                        </div>
        
                        <div class="timeline-item-inner">
                            <div class="timeline-dot-inner"></div>
                            <div class="timeline-content-inner">
                                <div class="timeline-year-inner">2022</div>
                                <div class="timeline-description-inner">
                                    Evobrutinib Phase III trials demonstrate superior efficacy compared to teriflunomide in relapsing MS, marking a potential paradigm shift in treatment approach.
                                </div>
                            </div>
                        </div>
                        <div class="timeline-item-inner">
                            <div class="timeline-dot-inner"></div>
                            <div class="timeline-content-inner">
                                <div class="timeline-year-inner">2023</div>
                                <div class="timeline-description-inner">
                                    Tolebrutinib shows groundbreaking results in progressive MS forms, expanding potential applications beyond relapsing MS
                                </div>
                            </div>
                        </div>
                        <div class="timeline-item-inner">
                            <div class="timeline-dot-inner"></div>
                            <div class="timeline-content-inner">
                                <div class="timeline-year-inner">2024</div>
                                <div class="timeline-description-inner">
                                    Development of next-generation selective BTK inhibitors with improved CNS penetration and reduced peripheral effects.
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>        

            <h2 class="section-title">Drug / Molecule Details</h2>
            <div class="container">
                <table>
                    <thead>
                        <tr>
                            <th>Drug Name</th>
                            <th>Company</th>
                            <th>Trial Count</th>
                            <th>Trial IDs</th>
                        </tr>
                    </thead>
                    <tbody>
                        <!-- Drug 1 -->
                        <tr class="drug-row" data-drug="remibrutinib">
                            <td>
                                <div class="drug-name">
                                    <span class="drug-icon">▼</span>
                                    Remibrutinib
                                </div>
                            </td>
                            <td class="company-cell">Novartis</td>
                            <td><span class="phase-badge">2</span></td>
                            <td>
                                <button class="trial-button" data-trial="NCT05156281">NCT05156281</button>
                                <button class="trial-button" data-trial="NCT05147220">NCT05147220</button>
                            </td>
                        </tr>
                        
                        <tr id="remibrutinib-insights" class="drug-insights">
                            <td colspan="4">
                                <div class="insights-container">
                                    <!-- <div class="insights-section">
                                        <h4>Latest Trial Results</h4>
                                        <p>Will be Updated</p>
                                    </div> -->
                                    <div class="insights-section">
                                        <h4>KOL Opinion</h4>
                                        <p>Leading experts in dermatology have voiced strong support for remibrutinib as a promising oral treatment for CSU. Martin Metz, a professor of dermatology, emphasized the importance of remibrutinib due to its ability to block the BTK cascade, reducing histamine release, which is critical in managing CSU symptoms. He noted that remibrutinib could become a valuable option for patients struggling with uncontrolled symptoms despite conventional treatments</p>
                                    </div>
                                    <div class="insights-section">
                                        <h4>Regulatory Information</h4>
                                        <p>Novartis is preparing regulatory filings for remibrutinib in the treatment of CSU in the second half of 2024. These submissions are expected to take place globally, based on the strong 52-week trial results. This filing is critical as Novartis seeks to position remibrutinib as a successor to Xolair (omalizumab), which is nearing patent expiration</p>
                                    </div>
                                </div>
                            </td>
                        </tr>
        
                        <!-- Trial Insights -->
                        <tr id="NCT05156281-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT05156281</h4>
                                    <p>Trial Phase: Phase II</p>
                                    <p>While the trial completion date for this study is projected to be in 2030, remibrutinib has already shown promising results in other conditions such as chronic spontaneous urticaria (CSU). Phase III trials of remibrutinib for CSU have met primary endpoints, showing rapid symptom control and a favorable safety profile. These findings suggest potential efficacy for its use in RMS, as remibrutinib continues to demonstrate sustained symptom relief and safety across several immune-mediated diseases
                                    </p>
                                </div>
                            </td>
                        </tr>
                        <tr id="NCT05147220-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT05147220</h4>
                                    <p>Trial Phase: Phase III</p>
                                    <p>The phase III trials, REMIX-1 and REMIX-2, have confirmed the long-term efficacy and safety of remibrutinib for treating chronic spontaneous urticaria (CSU). After 52 weeks, nearly half of the patients treated with remibrutinib were completely free of symptoms like hives and itching (UAS7 score of zero). These results were seen in patients who had previously been unresponsive to high-dose antihistamines. Remibrutinib showed rapid symptom relief, which was sustained over time. The safety profile remained consistent, with no significant differences in adverse events compared to placebo</p>
                                </div>
                            </td>
                        </tr>
        
                        <tr id="NCT72382624-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT05147220</h4>
                                    <p>Trial Phase: Phase II</p>
                                    <p>Latest results Will be Updated</p>
                                </div>
                            </td>
                        </tr>
                        <!-- Drug 2 -->
                        <tr class="drug-row" data-drug="sar443820">
                            <td>
                                <div class="drug-name">
                                    <span class="drug-icon">▼</span>
                                    Sar443820
                                </div>
                            </td>
                            <td class="company-cell">Sanofi</td>
                            <td><span class="phase-badge">1</span></td>
                            <td>
                                <button class="trial-button" data-trial="NCT05630547">NCT05630547</button>
                            </td>
                        </tr>
                        
                        <tr id="sar443820-insights" class="drug-insights">
                            <td colspan="4">
                                <div class="insights-container">
                                    <div class="insights-section">
                                        <h4>KOL Opinion</h4>
                                        <p>Key opinion leaders (KOLs) in the MS field generally acknowledge the potential of RIPK1 inhibitors, including Oditrasertib, due to their mechanism targeting inflammation and neuronal death pathways. However, the repeated clinical failures in both MS and ALS raise concerns about the efficacy of RIPK1 inhibitors in neurodegenerative conditions. The trial results have highlighted the complexity of developing treatments for MS, with KOLs suggesting a need for new approaches or better patient stratification to improve trial outcomes</p>
                                    </div>
                                    <div class="insights-section">
                                        <h4>Regulatory Information</h4>
                                        <p>Oditrasertib's Phase 2 trial (NCT05630547) was part of Sanofi and Denali's broader collaboration initiated in 2018 to develop RIPK1 inhibitors for various neurological and immunological diseases. After the trial's failure, no further regulatory milestones for Oditrasertib are expected in MS. The discontinuation marks a setback for the program, which had already seen failures in ALS trials earlier this year. Sanofi and Denali are now likely to focus on other drug candidates in their portfolio</p>
                                    </div>
                                </div>
                            </td>
                        </tr>
                        
                        <tr id="NCT05630547-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT05630547</h4>
                                    <p>Trial Phase: Phase II</p>
                                    <p>Sanofi has recently halted its Phase 2 trial of Oditrasertib (SAR443820), an investigational RIPK1 inhibitor, for multiple sclerosis (MS) after the trial failed to meet its primary and secondary endpoints. The trial, conducted in collaboration with Denali Therapeutics, aimed to lower neurofilament light chain (NfL) levels, a biomarker for neurodegeneration, in patients with relapsing-remitting, secondary progressive, and primary progressive MS. However, Oditrasertib did not significantly reduce NfL levels compared to the placebo, nor did it meet secondary goals related to brain volume, disability progression, and relapse rates</p>
                                </div>
                            </td>
                        </tr>
                        <!-- Drug -3 -->
                        <tr class="drug-row" data-drug="fenebrutinib">
                            <td>
                                <div class="drug-name">
                                    <span class="drug-icon">▼</span>
                                    Fenebrutinib
                                </div>
                            </td>
                            <td class="company-cell">Roche</td>
                            <td><span class="phase-badge">3</span></td>
                            <td>
                                <button class="trial-button" data-trial="NCT05119569">NCT05119569</button>
                                <button class="trial-button" data-trial="NCT04586023">NCT04586023</button>
                                <button class="trial-button" data-trial="NCT04586010">NCT04586010</button>
                            </td>
                        </tr>
                        <tr id="fenebrutinib-insights" class="drug-insights">
                            <td colspan="4">
                                <div class="insights-container">
                                    <div class="insights-section">
                                        <h4>Latest Trial Results</h4>
                                        <p>Roche's fenebrutinib, an investigational BTK inhibitor, has shown promising results in multiple sclerosis (MS) trials. In the Phase II FENopta study (NCT05119569), fenebrutinib significantly reduced new T1 gadolinium-enhancing lesions and T2-weighted brain lesions, key markers of MS activity, by 90-95% compared to placebo. Furthermore, after a year of treatment, 96% of participants were relapse-free, and 99% had no active inflammatory lesions on MRI scans. The drug also showed no disability progression, as measured by the Expanded Disability Status Scale (EDSS), and had a favorable safety profile, consistent with prior trials</p>
                                    </div>
                                    <div class="insights-section">
                                        <h4>KOL Opinion</h4>
                                        <p>KOLs have noted fenebrutinib’s potential to reshape MS treatment due to its dual action on B-cells and microglia, which may address both MS disease activity and progression. Dr. Levi Garraway, Roche's Chief Medical Officer, emphasized that fenebrutinib has the potential to suppress nearly all disease activity in people with MS and could become a major player if Phase III results confirm these early findings</p>
                                    </div>
                                    <div class="insights-section">
                                        <h4>Regulatory Information</h4>
                                        <p>Fenebrutinib is currently advancing through Phase III trials, with results expected by late 2025. These trials, known as FENhance 1 & 2, are evaluating fenebrutinib in relapsing multiple sclerosis (RMS), and FENtrepid is examining its efficacy in primary progressive MS (PPMS). If successful, fenebrutinib could follow Ocrevus as a significant treatment option, especially given its promising data on reducing both inflammation and disability progression.</p>
                                </div>
                            </td>
                        </tr>
        
                        <tr id="NCT05119569-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT05119569</h4>
                                    <p>Trial Phase: Phase II</p>
                                    <p>Roche's fenebrutinib, an investigational BTK inhibitor, has shown promising results in multiple sclerosis (MS) trials. In the Phase II FENopta study (NCT05119569), fenebrutinib significantly reduced new T1 gadolinium-enhancing lesions and T2-weighted brain lesions, key markers of MS activity, by 90-95% compared to placebo. Furthermore, after a year of treatment, 96% of participants were relapse-free, and 99% had no active inflammatory lesions on MRI scans. The drug also showed no disability progression, as measured by the Expanded Disability Status Scale (EDSS), and had a favorable safety profile, consistent with prior trials</p>
                                </div>
                            </td>
                        </tr>
                        <tr id="NCT04586023-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT04586023</h4>
                                    <p>Trial Phase: Phase II</p>
                                    <p>Fenebrutinib, a BTK (Bruton’s Tyrosine Kinase) inhibitor, has shown promising results in managing relapsing multiple sclerosis (MS). In Phase 2 trials, it reduced the number of new inflammatory brain lesions by over 90% compared to a placebo. Additionally, it significantly curbed disease activity in participants over 48 weeks, with 96% of patients being relapse-free and 99% showing no new active lesions on MRI scans. This outcome suggests that fenebrutinib is effective in controlling both relapses and disability progression in relapsing forms of MS</p>
                                </div>
                            </td>
                        </tr>
                        <tr id="NCT04586010-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT04586010</h4>
                                    <p>Trial Phase: Phase III</p>
                                    <p>Fenebrutinib has shown promising results in recent clinical studies. In Phase II trials, it demonstrated near-complete suppression of disease activity in relapsing MS. Specifically, 99% of patients were free from T1 gadolinium-enhancing lesions at 48 weeks, indicating minimal inflammation. The drug achieved an annualized relapse rate (ARR) of 0.04 over the trial period, with no significant change in disability measured via the Expanded Disability Status Scale (EDSS). These results suggest strong efficacy in reducing both disease activity and disability progression in relapsing MS</p>
                                </div>
                            </td>
                        </tr>
                        <!-- Drug 4 -->
                        <tr class="drug-row" data-drug="tolebrutinib">
                            <td>
                                <div class="drug-name">
                                    <span class="drug-icon">▼</span>
                                    Tolebrutinib
                                </div>
                            </td>
                            <td class="company-cell">Sanofi</td>
                            <td><span class="phase-badge">3</span></td>
                            <td>
                                <button class="trial-button" data-trial="NCT03996291">NCT03996291</button>
                                <button class="trial-button" data-trial="NCT04458051">NCT04458051</button>
                                <button class="trial-button" data-trial="NCT04411641">NCT04411641</button>
                            </td>
                        </tr>
                        <tr id="tolebrutinib-insights" class="drug-insights">
                            <td colspan="4">
                                <div class="insights-container">
                                    <div class="insights-section">
                                        <h4>KOL Opinion</h4>
                                        <p>Experts are optimistic about tolebrutinib’s potential. Dr. Jiwoh Oh from the University of Toronto emphasized the drug’s ability to stabilize relapse rates and limit new lesions. Sanofi's Dr. Erik Wallström highlighted its brain penetration and impact on MS disease progression, particularly in its ability to modulate inflammatory signaling in the brain</p>
                                    </div>
                                    <div class="insights-section">
                                        <h4>Regulatory Information</h4>
                                        <p>Tolebrutinib is currently undergoing evaluation in several phase 3 trials, including the GEMINI studies for relapsing MS and the HERCULES trial for non-relapsing secondary progressive MS (nrSPMS). However, a partial FDA clinical hold was implemented in 2022 due to concerns about drug-induced liver injury, impacting the timeline for approval. Sanofi aims to file for regulatory approval by the end of 2024</p>
                                </div>
                            </td>
                        </tr>
        
                        <tr id="NCT03996291-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT03996291</h4>
                                    <p>Trial Phase: Phase III</p>
                                    <p>Tolebrutinib, Sanofi's BTK inhibitor, has shown promising results in clinical trials for multiple sclerosis (MS). In long-term safety data from the phase 2b extension study (NCT03996291), patients with relapsing MS who were treated with tolebrutinib (60 mg daily) for 2.5 years showed stable annualized relapse rates (ARR) and low MRI lesion activity. Over 85% of participants remained on treatment, with common side effects including COVID-19, headache, and upper respiratory tract infections. However, the FDA placed a partial hold on phase 3 trials in 2022 due to liver toxicity concerns</p>
                                </div>
                            </td>
                        </tr>
                        <tr id="NCT04458051-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT04458051</h4>
                                    <p>Trial Phase: Phase III</p>
                                    <p>Tolebrutinib has shown promise in several ongoing trials. Though data specific to PERSEUS has not been fully released, its sister trials like GEMINI and HERCULES have revealed important insights:
                                        •	In the GEMINI studies, targeting relapsing forms of MS, tolebrutinib did not significantly reduce the annual relapse rate compared to teriflunomide. However, it did show a 29% lower risk of disability progression, which is crucial for addressing the long-term impact of MS
                                        •	In the HERCULES trial on non-relapsing secondary progressive MS (SPMS), tolebrutinib significantly delayed disability progression by 31% compared to placebo</p>
                                </div>
                            </td>
                        </tr>
                        <tr id="NCT04411641-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT04411641</h4>
                                    <p>Trial Phase: Phase III</p>
                                    <p>The HERCULES trial, a Phase 3 study, evaluated the efficacy of tolebrutinib in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS). Tolebrutinib demonstrated a 31% delay in the time to 6-month confirmed disability progression (CDP) compared to placebo, meeting its primary endpoint. Additionally, 10% of patients treated with tolebrutinib showed confirmed disability improvement, compared to 5% in the placebo group. These results highlight tolebrutinib’s potential in slowing the progression of disability in nrSPMS, a condition with few treatment options available</p>
                                </div>
                            </td>
                        </tr>
                        <!-- Drug 5 -->
                        <tr class="drug-row" data-drug="orelabrutinib">
                            <td>
                                <div class="drug-name">
                                    <span class="drug-icon">▼</span>
                                    Orelabrutinib
                                </div>
                            </td>
                            <td class="company-cell">Beijing InnoCare Pharma</td>
                            <td><span class="phase-badge">1</span></td>
                            <td>
                                <button class="trial-button" data-trial="NCT04711148">NCT04711148</button>
                            </td>
                        </tr>
                        <tr id="orelabrutinib-insights" class="drug-insights">
                            <td colspan="4">
                                <div class="insights-container">
                                    <div class="insights-section">
                                        <h4>KOL Opinion</h4>
                                        <p>Key opinion leaders (KOLs) have expressed optimism regarding orelabrutinib's unique characteristics, such as its ability to penetrate the blood-brain barrier and its high selectivity for BTK. Dr. Alfred Sandrock, Head of Research and Development at Biogen, has highlighted the potential for orelabrutinib to offer clinically meaningful benefits by addressing the underlying biology of MS, thus improving treatment outcomes. KOLs suggest that these advantages may differentiate orelabrutinib from other BTK inhibitors currently in development</p>
                                    </div>
                                    <div class="insights-section">
                                        <h4>Regulatory Information</h4>
                                        <p>Orelabrutinib has been approved in China for relapsed/refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). It is also advancing through global trials, with a Phase III trial initiated for primary progressive multiple sclerosis (PPMS) . In addition, InnoCare is expanding its trials to other autoimmune diseases, such as systemic lupus erythematosus (SLE) and immune thrombocytopenia purpura (ITP)</p>
                                </div>
                            </td>
                        </tr>
        
                        <tr id="NCT04711148-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT04711148</h4>
                                    <p>Trial Phase: Phase II</p>
                                    <p>Efficacy: Interim results from the trial indicate that orelabrutinib significantly reduces the number of new brain lesions associated with RRMS. Specifically, a 12-week analysis showed:
                                        o	71.1% relative reduction in lesions for those receiving 50 mg once daily.
                                        o	80.8% reduction for those receiving 50 mg twice daily.
                                        o	92.1% reduction for patients on the 80 mg once daily dose</p>
                                </div>
                            </td>
                        </tr>
                        <!-- Drug 6 -->
                        <tr class="drug-row" data-drug="biib091">
                            <td>
                                <div class="drug-name">
                                    <span class="drug-icon">▼</span>
                                    Biib091
                                </div>
                            </td>
                            <td class="company-cell">Biogen</td>
                            <td><span class="phase-badge">1</span></td>
                            <td>
                                <button class="trial-button" data-trial="NCT05798520">NCT05798520</button>
                            </td>
                        </tr>
                        <tr id="biib091-insights" class="drug-insights">
                            <td colspan="4">
                                <div class="insights-container">
                                    <div class="insights-section">
                                        <h4>KOL Opinion</h4>
                                        <p>Key opinion leaders (KOLs), such as Dr. Diana Gallagher, head of Biogen's MS and Immunology Department, have highlighted BIIB091’s potential. It is a reversible, non-covalent BTK inhibitor, which is designed to target both B cells and myeloid cells. According to KOLs, this dual-targeting mechanism could offer advantages over traditional B-cell depleting agents by providing enhanced efficacy while avoiding long-term safety concerns</p>
                                    </div>
                                    <div class="insights-section">
                                        <h4>Regulatory Information</h4>
                                        <p>The trial is currently in Phase 2, and its estimated completion date is November 2026. No major regulatory submissions have been made as of now, as the focus remains on gathering safety and efficacy data. BIIB091's development is being closely monitored, and if the results are positive, regulatory milestones such as submission for FDA approval could follow after the Phase 2 and subsequent trials</p>
                                </div>
                            </td>
                        </tr>
        
                        <tr id="NCT05798520-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT05798520</h4>
                                    <p>Trial Phase: Phase II</p>
                                    <p>The Phase 2 FUSION trial (NCT05798520) for Biogen's BIIB091 is currently in progress and focuses on relapsing forms of multiple sclerosis (MS). The study is assessing both BIIB091 as a monotherapy and in combination with Diroximel Fumarate (DRF), an approved MS therapy. Early-stage studies (SAD and MAD) have shown promising results in terms of B-cell suppression, which is critical in MS treatment. The primary endpoint in the first part of the trial is safety, while the second part focuses on MRI-based reductions in brain inflammation. The trial is expected to enroll 275 patients, with results expected by 2026</p>
                                </div>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="latest-insights">
                <h2>Latest Insights</h2>
                
                <!-- Clinical Breakthroughs -->
                <div class="insight-category">
                    <div class="insight-header clinical" onclick="toggleInsight(this)">
                        <div class="header-title">
                            <span class="category-icon">🔬</span>
                            Clinical Breakthroughs
                        </div>
                        <button class="toggle-btn">+</button>
                    </div>
                    <div class="insight-content">
                        <div class="insight-list">
                            <div class="insight-item">
                                <!-- <span class="insight-date">Oct 20, 2024</span> -->
                                <div class="insight-description">
                                    BTK inhibitors are gaining attention as a novel therapeutic approach for MS. Their ability to modulate B-cell activity and other immune responses presents a promising strategy to target the underlying autoimmune processes in MS.
                                    
                                </div>
                            </div>
                            <div class="insight-item">
                                <!-- <span class="insight-date">Oct 15, 2024</span> -->
                                <div class="insight-description">
                                    Bruton tyrosine kinase (BTK) inhibitors are emerging as a promising class of therapies for multiple sclerosis (MS), targeting immune cells across the blood-brain barrier. Notable BTK inhibitors currently under investigation include evobrutinib (Merck KGaA/EMD Serono), tolebrutinib (Sanofi), and orelabrutinib (Biogen/InnoCare Pharma). Early clinical trial data and preclinical studies suggest that these agents may effectively modulate immune responses and reduce inflammation associated with MS.
                                </div>
                            </div>
                            <div class="insight-item">
                                <!-- <span class="insight-date">Oct 15, 2024</span> -->
                                <div class="insight-description">
                                    Clinical Efficacy: Several BTK inhibitors are undergoing investigation
                                    <br>
                                    <span class="insight-date">Evobrutinib (Merck KGaA/EMD Serono): Showed acceptable tolerability and maintained efficacy in a phase 2 study over 2.5 years, although it failed to meet primary endpoints in subsequent phase 3 trials.</span>
                                    <span class="insight-date">Fenebrutinib (Roche): Demonstrated significant reductions in MRI markers of MS activity and a favorable safety profile, although it faced safety concerns related to liver function.</span>
                                    <span class="insight-date">Tolebrutinib (Sanofi): Reported a 60 mg/d dosage reduced T1 gadolinium-enhancing lesions by approximately 85%, with stable Expanded Disability Status Scale (EDSS) scores over time.</span>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            
                <!-- Safety and Tolerability -->
                <div class="insight-category">
                    <div class="insight-header regulatory" onclick="toggleInsight(this)">
                        <div class="header-title">
                            <span class="category-icon">🛡️</span>
                            Safety and Tolerability
                        </div>
                        <button class="toggle-btn">+</button>
                    </div>
                    <div class="insight-content">
                        <div class="insight-list">
                            <div class="insight-item">
                                <div class="insight-description">
                                    Liver Enzyme Elevations
                                    <br>
                                    In the phase 3 HERCULES trial, liver enzyme elevations were noted in tolebrutinib-treated patients, with 4.1% experiencing levels >3x the upper limit of normal (ULN). Most cases resolved without intervention. A serious case resulted in a liver transplant, highlighting the need for stringent monitoring
                                    
                                </div>
                            </div>
                            <div class="insight-item">
                                <div class="insight-description">
                                    Risk Mitigation
                                    <br>
                                    Following initial concerns about liver injuries, the study protocols were revised to enhance safety monitoring and exclude patients with preexisting hepatic issues, which helped address some of the earlier safety concerns
                                    
                                </div>
                            </div>
                            <div class="insight-item">
                                <div class="insight-description">
                                    Adverse Events (AEs)
                                    <br>
                                    Common AEs reported in clinical trials included headache (12.8%), COVID-19 (12.8%), and upper respiratory tract infections (8.0%). Importantly, there were no new safety signals identified during treatment
                                    
                                </div>
                            </div>
                            <div class="insight-item">
                                <div class="insight-description">
                                    Long-Term Safety
                                    <br>
                                    Tolebrutinib has shown favorable long-term safety in open-label studies. Patients transitioning to a consistent 60 mg dose reported low incidences of new gadolinium-enhancing lesions, suggesting effective control of disease activity
                                    
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            
                <!-- Regulatory Milestones -->
                <div class="insight-category">
                    <div class="insight-header safety" onclick="toggleInsight(this)">
                        <div class="header-title">
                            <span class="category-icon">📋</span>
                            Regulatory Milestones
                        </div>
                        <button class="toggle-btn">+</button>
                    </div>
                    <div class="insight-content">
                        <div class="insight-list">
                            <div class="insight-item">
                                <div class="insight-description">
                                    1.	Tolebrutinib (Sanofi):
                                    <br>
                                    •	Received FDA Fast Track Designation
                                    <br>
                                    •	Phase III trials ongoing as of early 2024
                                    <br>
                                    •	FDA placed partial clinical holds on Phase III trials in 2022 due to liver safety concerns
                                    <br>
                                    •	Hold was partially lifted for some patient populations
                                    
                                </div>
                            </div>
                            <div class="insight-item">
                                <div class="insight-description">
                                    2.	Fenebrutinib (Genentech/Roche):
                                    <br>
                                    •	Phase III clinical trials ongoing as of early 2024
                                    <br>
                                    •	FENhance trials investigating its use in RMS and PPMS

                                    
                                </div>
                            </div>
                            <div class="insight-item">
                                <div class="insight-description">
                                    3.	Orelabrutinib (InnoCare):
                                    <br>
                                    •	Received FDA Fast Track Designation for RMS
                                    <br>
                                    •	Phase II trials completed with positive results
                                    <br>
                                    •	Phase III trials initiated
                                    
                                    
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>

        <!-- anticd20 -->
        <div id="anti20-details" class="moa-details">
            <div class="metrics-grid">
                <div class="metric-card">
                    <h3>Total Trials</h3>
                    <div class="metric-value">11</div>
                </div>
                <div class="metric-card">
                    <h3>Total Competitors</h3>
                    <div class="metric-value">5</div>
                </div>
                <div class="metric-card">
                    <h3>Drug Count</h3>
                    <div class="metric-value">6</div>
                </div>
            </div>

            <div class="charts-section">
                <div class="chart-container">
                    <canvas id="anticd20-phase-chart"></canvas>
                </div>
                <div class="chart-container">
                    <canvas id="anticd20-market-chart"></canvas>
                </div>
            </div>
            <h2 class="section-title">BTK Inhibitors Time Line</h2>
            <div class="timeline-container-inner">
                <div class="timeline-inner">
                    <div class="timeline-items-inner">
                        <div class="timeline-item-inner">
                            <div class="timeline-dot-inner"></div>
                            <div class="timeline-content-inner">
                                <div class="timeline-year-inner">2019</div>
                                <div class="timeline-description-inner">
                                    Breakthrough discovery: First demonstration of BTK inhibitor evobrutinib's efficacy in reducing MS lesions in Phase II trials, establishing BTK as a viable therapeutic target in MS.
                                </div>
                            </div>
                        </div>
        
                        <div class="timeline-item-inner">
                            <div class="timeline-dot-inner"></div>
                            <div class="timeline-content-inner">
                                <div class="timeline-year-inner">2020</div>
                                <div class="timeline-description-inner">
                                    olebrutinib emerges as a leading CNS-penetrant BTK inhibitor with positive Phase II results showing significant reduction in brain lesions and clinical outcomes.
                                </div>
                            </div>
                        </div>
        
                        <div class="timeline-item-inner">
                            <div class="timeline-dot-inner"></div>
                            <div class="timeline-content-inner">
                                <div class="timeline-year-inner">2021</div>
                                <div class="timeline-description-inner">
                                    Fenebrutinib launches pivotal Phase III FENhance clinical trial program, marking the expansion of BTK inhibitor options in MS treatment landscape.
                                </div>
                            </div>
                        </div>
        
                        <div class="timeline-item-inner">
                            <div class="timeline-dot-inner"></div>
                            <div class="timeline-content-inner">
                                <div class="timeline-year-inner">2022</div>
                                <div class="timeline-description-inner">
                                    Evobrutinib Phase III trials demonstrate superior efficacy compared to teriflunomide in relapsing MS, marking a potential paradigm shift in treatment approach.
                                </div>
                            </div>
                        </div>
                        <div class="timeline-item-inner">
                            <div class="timeline-dot-inner"></div>
                            <div class="timeline-content-inner">
                                <div class="timeline-year-inner">2023</div>
                                <div class="timeline-description-inner">
                                    Tolebrutinib shows groundbreaking results in progressive MS forms, expanding potential applications beyond relapsing MS
                                </div>
                            </div>
                        </div>
                        <div class="timeline-item-inner">
                            <div class="timeline-dot-inner"></div>
                            <div class="timeline-content-inner">
                                <div class="timeline-year-inner">2024</div>
                                <div class="timeline-description-inner">
                                    Development of next-generation selective BTK inhibitors with improved CNS penetration and reduced peripheral effects.
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>        

            <h2 class="section-title">Drug / Molecule Details</h2>
            <div class="container">
                <table>
                    <thead>
                        <tr>
                            <th>Drug Name</th>
                            <th>Company</th>
                            <th>Trail Count</th>
                            <th>Clinical Trials</th>
                        </tr>
                    </thead>
                    <tbody>
                        <!-- Drug 1 -->
                        <tr class="drug-row" data-drug="remibrutinib">
                            <td>
                                <div class="drug-name">
                                    <span class="drug-icon">▼</span>
                                    Remibrutinib
                                </div>
                            </td>
                            <td class="company-cell">Novartis</td>
                            <td><span class="phase-badge">2</span></td>
                            <td>
                                <button class="trial-button" data-trial="NCT05156281">NCT05156281</button>
                                <button class="trial-button" data-trial="NCT05147220">NCT05147220</button>
                            </td>
                        </tr>
                        
                        <tr id="remibrutinib-insights" class="drug-insights">
                            <td colspan="4">
                                <div class="insights-container">
                                    <div class="insights-section">
                                        <h4>Latest Trial Results</h4>
                                        <p>Will be Updated</p>
                                    </div>
                                    <div class="insights-section">
                                        <h4>KOL Opinion</h4>
                                        <p>Will be Updated</p>
                                    </div>
                                    <div class="insights-section">
                                        <h4>Regulatory Information</h4>
                                        <p>Will be Updated</p>
                                    </div>
                                </div>
                            </td>
                        </tr>
        
                        <!-- Trial Insights -->
                        <tr id="NCT05156281-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT05156281</h4>
                                    <p>Trial Phase: Phase II</p>
                                    <p>Latest results Will be Updated</p>
                                </div>
                            </td>
                        </tr>
                        <tr id="NCT05147220-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT05147220</h4>
                                    <p>Trial Phase: Phase II</p>
                                    <p>Latest results Will be Updated</p>
                                </div>
                            </td>
                        </tr>
        
                        <tr id="NCT72382624-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT05147220</h4>
                                    <p>Trial Phase: Phase II</p>
                                    <p>Latest results Will be Updated</p>
                                </div>
                            </td>
                        </tr>
                        <!-- Drug 2 -->
                        <tr class="drug-row" data-drug="sar443820">
                            <td>
                                <div class="drug-name">
                                    <span class="drug-icon">▼</span>
                                    Sar443820
                                </div>
                            </td>
                            <td class="company-cell">Sanofi</td>
                            <td><span class="phase-badge">1</span></td>
                            <td>
                                <button class="trial-button" data-trial="NCT05630547">NCT05630547</button>
                            </td>
                        </tr>
                        
                        <tr id="sar443820-insights" class="drug-insights">
                            <td colspan="4">
                                <div class="insights-container">
                                    <div class="insights-section">
                                        <h4>Latest Trial Results</h4>
                                        <p>Will be Updated</p>
                                    </div>
                                    <div class="insights-section">
                                        <h4>KOL Opinion</h4>
                                        <p>Will be Updated</p>
                                    </div>
                                    <div class="insights-section">
                                        <h4>Regulatory Information</h4>
                                        <p>Will be Updated</p>
                                    </div>
                                </div>
                            </td>
                        </tr>
                        
                        <tr id="NCT05630547-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT05630547</h4>
                                    <p>Trial Phase: Phase I</p>
                                    <p>Latest results Will be Updated</p>
                                </div>
                            </td>
                        </tr>
                        <!-- Drug -3 -->
                        <tr class="drug-row" data-drug="fenebrutinib">
                            <td>
                                <div class="drug-name">
                                    <span class="drug-icon">▼</span>
                                    Fenebrutinib
                                </div>
                            </td>
                            <td class="company-cell">Roche</td>
                            <td><span class="phase-badge">3</span></td>
                            <td>
                                <button class="trial-button" data-trial="NCT05119569">NCT05119569</button>
                                <button class="trial-button" data-trial="NCT04586023">NCT04586023</button>
                                <button class="trial-button" data-trial="NCT04586010">NCT04586010</button>
                            </td>
                        </tr>
                        <tr id="fenebrutinib-insights" class="drug-insights">
                            <td colspan="4">
                                <div class="insights-container">
                                    <div class="insights-section">
                                        <h4>Latest Trial Results</h4>
                                        <p>Will be Updated</p>
                                    </div>
                                    <div class="insights-section">
                                        <h4>KOL Opinion</h4>
                                        <p>Will be Updated</p>
                                    </div>
                                    <div class="insights-section">
                                        <h4>Regulatory Information</h4>
                                        <p>Will be Updated</p>
                                </div>
                            </td>
                        </tr>
        
                        <tr id="NCT05119569-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT05119569</h4>
                                    <p>Trial Phase: Phase II</p>
                                    <p>Latest results Will be Updated</p>
                                </div>
                            </td>
                        </tr>
                        <tr id="NCT04586023-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT04586023</h4>
                                    <p>Trial Phase: Phase II</p>
                                    <p>Latest results Will be Updated</p>
                                </div>
                            </td>
                        </tr>
                        <tr id="NCT04586010-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT04586010</h4>
                                    <p>Trial Phase: Phase II</p>
                                    <p>Latest results Will be Updated</p>
                                </div>
                            </td>
                        </tr>
                        <!-- Drug 4 -->
                        <tr class="drug-row" data-drug="tolebrutinib">
                            <td>
                                <div class="drug-name">
                                    <span class="drug-icon">▼</span>
                                    Tolebrutinib
                                </div>
                            </td>
                            <td class="company-cell">Sanofi</td>
                            <td><span class="phase-badge">3</span></td>
                            <td>
                                <button class="trial-button" data-trial="NCT03996291">NCT03996291</button>
                                <button class="trial-button" data-trial="NCT04458051">NCT04458051</button>
                                <button class="trial-button" data-trial="NCT04411641">NCT04411641</button>
                            </td>
                        </tr>
                        <tr id="tolebrutinib-insights" class="drug-insights">
                            <td colspan="4">
                                <div class="insights-container">
                                    <div class="insights-section">
                                        <h4>Latest Trial Results</h4>
                                        <p>Will be Updated</p>
                                    </div>
                                    <div class="insights-section">
                                        <h4>KOL Opinion</h4>
                                        <p>Will be Updated</p>
                                    </div>
                                    <div class="insights-section">
                                        <h4>Regulatory Information</h4>
                                        <p>Will be Updated</p>
                                </div>
                            </td>
                        </tr>
        
                        <tr id="NCT03996291-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT03996291</h4>
                                    <p>Trial Phase: Phase III</p>
                                    <p>Latest results Will be Updated</p>
                                </div>
                            </td>
                        </tr>
                        <tr id="NCT04458051-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT04458051</h4>
                                    <p>Trial Phase: Phase III</p>
                                    <p>Latest results Will be Updated</p>
                                </div>
                            </td>
                        </tr>
                        <tr id="NCT04411641-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT04411641</h4>
                                    <p>Trial Phase: Phase III</p>
                                    <p>Latest results Will be Updated</p>
                                </div>
                            </td>
                        </tr>
                        <!-- Drug 5 -->
                        <tr class="drug-row" data-drug="orelabrutinib">
                            <td>
                                <div class="drug-name">
                                    <span class="drug-icon">▼</span>
                                    Orelabrutinib
                                </div>
                            </td>
                            <td class="company-cell">Beijing InnoCare Pharma</td>
                            <td><span class="phase-badge">1</span></td>
                            <td>
                                <button class="trial-button" data-trial="NCT04711148">NCT04711148</button>
                            </td>
                        </tr>
                        <tr id="orelabrutinib-insights" class="drug-insights">
                            <td colspan="4">
                                <div class="insights-container">
                                    <div class="insights-section">
                                        <h4>Latest Trial Results</h4>
                                        <p>Will be Updated</p>
                                    </div>
                                    <div class="insights-section">
                                        <h4>KOL Opinion</h4>
                                        <p>Will be Updated</p>
                                    </div>
                                    <div class="insights-section">
                                        <h4>Regulatory Information</h4>
                                        <p>Will be Updated</p>
                                </div>
                            </td>
                        </tr>
        
                        <tr id="NCT04711148-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT04711148</h4>
                                    <p>Trial Phase: Phase I</p>
                                    <p>Latest results Will be Updated</p>
                                </div>
                            </td>
                        </tr>
                        <!-- Drug 6 -->
                        <tr class="drug-row" data-drug="biib091">
                            <td>
                                <div class="drug-name">
                                    <span class="drug-icon">▼</span>
                                    Biib091
                                </div>
                            </td>
                            <td class="company-cell">Biogen</td>
                            <td><span class="phase-badge">1</span></td>
                            <td>
                                <button class="trial-button" data-trial="NCT05798520">NCT05798520</button>
                            </td>
                        </tr>
                        <tr id="biib091-insights" class="drug-insights">
                            <td colspan="4">
                                <div class="insights-container">
                                    <div class="insights-section">
                                        <h4>Latest Trial Results</h4>
                                        <p>Will be Updated</p>
                                    </div>
                                    <div class="insights-section">
                                        <h4>KOL Opinion</h4>
                                        <p>Will be Updated</p>
                                    </div>
                                    <div class="insights-section">
                                        <h4>Regulatory Information</h4>
                                        <p>Will be Updated</p>
                                </div>
                            </td>
                        </tr>
        
                        <tr id="NCT05798520-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT05798520</h4>
                                    <p>Trial Phase: Phase II</p>
                                    <p>Latest results Will be Updated</p>
                                </div>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="latest-insights">
                <h2>Latest Insights</h2>
                
                <!-- Clinical Breakthroughs -->
                <div class="insight-category">
                    <div class="insight-header clinical" onclick="toggleInsight(this)">
                        <div class="header-title">
                            <span class="category-icon">🔬</span>
                            Clinical Breakthroughs
                        </div>
                        <button class="toggle-btn">+</button>
                    </div>
                    <div class="insight-content">
                        <div class="insight-list">
                            <div class="insight-item">
                                <!-- <span class="insight-date">Oct 20, 2024</span> -->
                                <div class="insight-description">
                                    BTK inhibitors are gaining attention as a novel therapeutic approach for MS. Their ability to modulate B-cell activity and other immune responses presents a promising strategy to target the underlying autoimmune processes in MS.
                                    <span class="badge new">New</span>
                                </div>
                            </div>
                            <div class="insight-item">
                                <!-- <span class="insight-date">Oct 15, 2024</span> -->
                                <div class="insight-description">
                                    Bruton tyrosine kinase (BTK) inhibitors are emerging as a promising class of therapies for multiple sclerosis (MS), targeting immune cells across the blood-brain barrier. Notable BTK inhibitors currently under investigation include evobrutinib (Merck KGaA/EMD Serono), tolebrutinib (Sanofi), and orelabrutinib (Biogen/InnoCare Pharma). Early clinical trial data and preclinical studies suggest that these agents may effectively modulate immune responses and reduce inflammation associated with MS.
                                </div>
                            </div>
                            <div class="insight-item">
                                <!-- <span class="insight-date">Oct 15, 2024</span> -->
                                <div class="insight-description">
                                    Clinical Efficacy: Several BTK inhibitors are undergoing investigation
                                    <br>
                                    <span class="insight-date">Evobrutinib (Merck KGaA/EMD Serono): Showed acceptable tolerability and maintained efficacy in a phase 2 study over 2.5 years, although it failed to meet primary endpoints in subsequent phase 3 trials.</span>
                                    <span class="insight-date">Fenebrutinib (Roche): Demonstrated significant reductions in MRI markers of MS activity and a favorable safety profile, although it faced safety concerns related to liver function.</span>
                                    <span class="insight-date">Tolebrutinib (Sanofi): Reported a 60 mg/d dosage reduced T1 gadolinium-enhancing lesions by approximately 85%, with stable Expanded Disability Status Scale (EDSS) scores over time.</span>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            
                <!-- Regulatory Updates -->
                <div class="insight-category">
                    <div class="insight-header regulatory" onclick="toggleInsight(this)">
                        <div class="header-title">
                            <span class="category-icon">🛡️</span>
                            Safety and Tolerability
                        </div>
                        <button class="toggle-btn">+</button>
                    </div>
                    <div class="insight-content">
                        <div class="insight-list">
                            <div class="insight-item">
                                <div class="insight-description">
                                    Liver Enzyme Elevations
                                    <br>
                                    In the phase 3 HERCULES trial, liver enzyme elevations were noted in tolebrutinib-treated patients, with 4.1% experiencing levels >3x the upper limit of normal (ULN). Most cases resolved without intervention. A serious case resulted in a liver transplant, highlighting the need for stringent monitoring
                                    <span class="badge update">Update</span>
                                </div>
                            </div>
                            <div class="insight-item">
                                <div class="insight-description">
                                    Risk Mitigation
                                    <br>
                                    Following initial concerns about liver injuries, the study protocols were revised to enhance safety monitoring and exclude patients with preexisting hepatic issues, which helped address some of the earlier safety concerns
                                    <span class="badge update">Update</span>
                                </div>
                            </div>
                            <div class="insight-item">
                                <div class="insight-description">
                                    Adverse Events (AEs)
                                    <br>
                                    Common AEs reported in clinical trials included headache (12.8%), COVID-19 (12.8%), and upper respiratory tract infections (8.0%). Importantly, there were no new safety signals identified during treatment
                                    <span class="badge update">Update</span>
                                </div>
                            </div>
                            <div class="insight-item">
                                <div class="insight-description">
                                    Long-Term Safety
                                    <br>
                                    Tolebrutinib has shown favorable long-term safety in open-label studies. Patients transitioning to a consistent 60 mg dose reported low incidences of new gadolinium-enhancing lesions, suggesting effective control of disease activity
                                    <span class="badge update">Update</span>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            
                <!-- Regulatory Milestones -->
                <div class="insight-category">
                    <div class="insight-header safety" onclick="toggleInsight(this)">
                        <div class="header-title">
                            <span class="category-icon">📋</span>
                            Regulatory Milestones
                        </div>
                        <button class="toggle-btn">+</button>
                    </div>
                    <div class="insight-content">
                        <div class="insight-list">
                            <div class="insight-item">
                                <div class="insight-description">
                                    1.	Tolebrutinib (Sanofi):
                                    <br>
                                    •	Received FDA Fast Track Designation
                                    <br>
                                    •	Phase III trials ongoing as of early 2024
                                    <br>
                                    •	FDA placed partial clinical holds on Phase III trials in 2022 due to liver safety concerns
                                    <br>
                                    •	Hold was partially lifted for some patient populations
                                    <span class="badge new">New</span>
                                </div>
                            </div>
                            <div class="insight-item">
                                <div class="insight-description">
                                    2.	Fenebrutinib (Genentech/Roche):
                                    <br>
                                    •	Phase III clinical trials ongoing as of early 2024
                                    <br>
                                    •	FENhance trials investigating its use in RMS and PPMS

                                    <span class="badge new">New</span>
                                </div>
                            </div>
                            <div class="insight-item">
                                <div class="insight-description">
                                    3.	Orelabrutinib (InnoCare):
                                    <br>
                                    •	Received FDA Fast Track Designation for RMS
                                    <br>
                                    •	Phase II trials completed with positive results
                                    <br>
                                    •	Phase III trials initiated
                                    
                                    <span class="badge new">New</span>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>

    <script>
        function toggleMOA(moa, button) {
            const details = document.getElementById(`${moa}-details`);
            const allButtons = document.querySelectorAll('.moa-button');
            
            // Remove active class from all buttons
            allButtons.forEach(btn => btn.classList.remove('active'));
            
            if (details.style.display === 'none' || !details.style.display) {
                // Hide all MOA details first
                document.querySelectorAll('.moa-details').forEach(detail => {
                    detail.style.display = 'none';
                });
                
                details.style.display = 'block';
                button.classList.add('active');
                initializeCharts(moa);
            } else {
                details.style.display = 'none';
                button.classList.remove('active');
            }
        }

        document.addEventListener('DOMContentLoaded', function() {
            // Drug row click handlers
            document.querySelectorAll('.drug-row').forEach(row => {
                row.addEventListener('click', function(e) {
                    if (e.target.classList.contains('trial-button')) {
                        return; // Don't handle drug row click if trial button was clicked
                    }
                    
                    const drugId = this.getAttribute('data-drug');
                    const insights = document.getElementById(`${drugId}-insights`);
                    
                    // Close all other drug insights
                    document.querySelectorAll('.drug-insights').forEach(insight => {
                        if (insight !== insights) {
                            insight.classList.remove('show');
                        }
                    });
                    
                    // Remove active class from all rows
                    document.querySelectorAll('.drug-row').forEach(r => {
                        if (r !== this) {
                            r.classList.remove('active');
                        }
                    });
                    
                    // Toggle current drug insights
                    this.classList.toggle('active');
                    insights.classList.toggle('show');
                    
                    // Close all trial insights when toggling drug insights
                    document.querySelectorAll('.trial-insights').forEach(insight => {
                        insight.classList.remove('show');
                    });
                    document.querySelectorAll('.trial-button').forEach(button => {
                        button.classList.remove('active');
                    });
                });
            });

            // Trial button click handlers
            document.querySelectorAll('.trial-button').forEach(button => {
                button.addEventListener('click', function(e) {
                    e.stopPropagation(); // Prevent drug row click
                    
                    const trialId = this.getAttribute('data-trial');
                    const insights = document.getElementById(`${trialId}-insights`);
                    
                    // Close all other trial insights
                    document.querySelectorAll('.trial-insights').forEach(insight => {
                        if (insight !== insights) {
                            insight.classList.remove('show');
                        }
                    });
                    
                    // Remove active class from all trial buttons
                    document.querySelectorAll('.trial-button').forEach(btn => {
                        if (btn !== this) {
                            btn.classList.remove('active');
                        }
                    });
                    
                    // Toggle current trial insights and button state
                    this.classList.toggle('active');
                    insights.classList.toggle('show');
                });
            });
        });


        function initializeCharts(moa) {
            // Phase Distribution Chart
            const phaseCtx = document.getElementById(`${moa}-phase-chart`).getContext('2d');
            new Chart(phaseCtx, {
                type: 'bar',
                data: {
                    labels: ['Phase 1', 'Phase 2', 'Phase 3'],
                    datasets: [{
                        label: 'Number of Drugs',
                        data: [0, 5, 6],
                        backgroundColor: '#4299e1'
                    }]
                },
                options: {
                    responsive: true,
                    maintainAspectRatio: false,
                    plugins: {
                        title: {
                            display: true,
                            text: 'Drug Phase Distribution'
                        }
                    }
                }
            });

            // Market Share Chart
            const marketCtx = document.getElementById(`${moa}-market-chart`).getContext('2d');
            new Chart(marketCtx, {
                type: 'pie',
                data: {
                    labels: ['Sanofi', 'Novartis', 'Beijing InnoCare Pharma','Roche','Biogen'],
                    datasets: [{
                        data: [36,18,9.5,27,9.5],
                        backgroundColor: ['#4299e1', '#48bb78', '#ed8936', '#9f7aea', '#f56565']
                    }]
                },
                options: {
                    responsive: true,
                    maintainAspectRatio: false,
                    plugins: {
                        title: {
                            display: true,
                            text: 'Market Share Distribution'
                        }
                    }
                }
            });
        }
        function toggleInsight(header) {
            const content = header.nextElementSibling;
            const toggleBtn = header.querySelector('.toggle-btn');
            const allContents = document.querySelectorAll('.insight-content');
            const allToggleBtns = document.querySelectorAll('.toggle-btn');

            // Close all other sections
            allContents.forEach(item => {
                if (item !== content && item.classList.contains('active')) {
                    item.classList.remove('active');
                    item.previousElementSibling.querySelector('.toggle-btn').textContent = '+';
                }
            });

            // Toggle current section
            content.classList.toggle('active');
            toggleBtn.textContent = content.classList.contains('active') ? '−' : '+';
        }

    </script>

</body>
</html>